EU regulators knock back Valio blood pressure claim

摘要

The Finnish dairy company had applied to use the claim "helps to maintain normal blood pressure" for a combination of the tripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP). While the panel accepted that maintenance of normal blood pressure is a beneficial physiological effect, it found the studies submitted by the Finnish dairy group unconvincing. For example, the panel found that interpretation of the results from seven (out of eight) studies showing an effect of the product on office systolic blood pressure "was hampered by major methodological limitations." The animal studies failed to provide any additional information on the effect of IPP and VPP on blood pressure in humans, and the panel said that Valio had not provided any convincing evidence for a mechanism by which the product could exert the claimed effect at the proposed dose. As a result, the panel concluded that a cause and effect relationship has not been established between the consumption of IPP and VPP and maintenance of normal blood pressure.